A Phase III, Randomised, Double-blind, Parallel Group Study to Compare the Efficacy of AZD2171 (30 mg) in Combination with Gemcitabine and Cisplatin versus the Efficacy of Gemcitabine and Cisplatin alone in Patients with Locally Advanced or Metastatic (Stage IIIb/IV) Non Small Cell Lung Cancer.
Study identifier:D8480C00034
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Phase III, Randomised, Double-blind, Parallel Group Study to Compare the Efficacy of AZD2171 (30 mg) in Combination with Gemcitabine and Cisplatin versus the Efficacy of Gemcitabine and Cisplatin alone in Patients with Locally Advanced or Metastatic (Stage IIIb/IV) Non Small Cell Lung Cancer.
Medical condition
Non-small Cell Lung Cancer
Phase
Phase 3
Healthy volunteers
-
Study drug
-
Sex
-
Actual Enrollment
-
Study type
Interventional
Age
-
Date
Study Start Date: 01 Jan 1971
Primary Completion Date: -
Study Completion Date: -
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
-
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
